Predicting Radiation Pneumonitis After Stereotactic Ablative Radiation Therapy in Patients Previously Treated With Conventional Thoracic Radiation Therapy

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
International journal of radiation oncology, biology, physics (Impact Factor: 4.26). 04/2012; 84(4):1017-23. DOI: 10.1016/j.ijrobp.2012.02.020
Source: PubMed


To determine the incidence of and risk factors for radiation pneumonitis (RP) after stereotactic ablative radiation therapy (SABR) to the lung in patients who had previously undergone conventional thoracic radiation therapy.
Seventy-two patients who had previously received conventionally fractionated radiation therapy to the thorax were treated with SABR (50 Gy in 4 fractions) for recurrent disease or secondary parenchymal lung cancer (T <4 cm, N0, M0, or Mx). Severe (grade ≥3) RP and potential predictive factors were analyzed by univariate and multivariate logistic regression analyses. A scoring system was established to predict the risk of RP.
At a median follow-up time of 16 months after SABR (range, 4-56 months), 15 patients had severe RP (14 [18.9%] grade 3 and 1 [1.4%] grade 5) and 1 patient (1.4%) had a local recurrence. In univariate analyses, Eastern Cooperative Oncology Group performance status (ECOG PS) before SABR, forced expiratory volume in 1 second (FEV1), and previous planning target volume (PTV) location were associated with the incidence of severe RP. The V(10) and mean lung dose (MLD) of the previous plan and the V(10)-V(40) and MLD of the composite plan were also related to RP. Multivariate analysis revealed that ECOG PS scores of 2-3 before SABR (P=.009), FEV1 ≤65% before SABR (P=.012), V(20) ≥30% of the composite plan (P=.021), and an initial PTV in the bilateral mediastinum (P=.025) were all associated with RP.
We found that severe RP was relatively common, occurring in 20.8% of patients, and could be predicted by an ECOG PS score of 2-3, an FEV1 ≤65%, a previous PTV spanning the bilateral mediastinum, and V(20) ≥30% on composite (previous RT+SABR) plans. Prospective studies are needed to validate these predictors and the scoring system on which they are based.


Available from: Hui Liu, Apr 04, 2014
  • Source
    • "Guckenberger et al. ont montré que les variations de forced vital capacity in 1s (FEV1) et de diffusion du monoxyde de carbone étaient respectivement de −1,4 % (intervalle de confiance à 95 % [IC95 %] = –3,4 %–0) et −7,6 % (IC95 % = –10,2 %–3,4 %) à 6 mois après la radiothérapie en conditions stéréotaxiques [46]. La radiothérapie en conditions stéréotaxiques peut être effectuée chez des patients antérieurement irradiés, ainsi, Liu et al. ont obtenu chez 72 patients une seule rechute locale et des taux de survie sans récidive et de survie globale respectivement de 74,4 et 41,8 % [47]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stereotactic body radiation therapy for lung cancer is now well established for patients who are not eligible to surgery. These patients can benefit from a curative treatment, which is a new therapeutic indication. Protocols are effective and well tolerated even for the most fragile patients. Three randomized trials comparing stereotactic body radiation therapy and surgery failed due to poor accrual. However, taking into account the favourable available data, the choice of stereotactic body radiation therapy in first intention arises. The treatment decision has to be discussed in a multidisciplinary way, while considering the opinion of the patient, who must be clearly informed about the principle of both therapeutic options.
    Cancer/Radiothérapie 09/2015; 19(6). DOI:10.1016/j.canrad.2015.06.014 · 1.41 Impact Factor
  • Source
    • "The advantage of proton therapy hinges on its ability to minimize dose to normal tissues distal to the tumor. Thus, potential clinical benefit may be offered to patients with limited pulmonary reserve, tumors in close geometric proximity to critical normal structures, or in patients who have received prior thoracic radiation [7, 8]. In these cases, reducing radiation damage to normal tissues is an absolute priority. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stereotactic ablative radiotherapy (SABR), a recent implementation in the practice of radiation oncology, has been shown to confer high rates of local control in the treatment of early stage non-small-cell lung cancer (NSCLC). This technique, which involves limited invasive procedures and reduced treatment intervals, offers definitive treatment for patients unable or unwilling to undergo an operation. The use of protons in SABR delivery confers the added physical advantage of normal tissue sparing due to the absence of collateral radiation dose delivered to regions distal to the target. This may translate into clinical benefit and a decreased risk of clinical toxicity in patients with nearby critical structures or limited pulmonary reserve. In this review, we present the rationale for proton-based SABR, principles relating to the delivery and planning of this modality, and a summary of published clinical studies.
    BioMed Research International 07/2014; 2014:389048. DOI:10.1155/2014/389048 · 1.58 Impact Factor
  • Source
    • "At MDACC, Kelly et al. reported outcomes of 36 patients with prior thoracic radiation, however only 11 patients had received SBRT for what was defined as in-field relapses [12]. An updated report increased this number to 19 [19]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Management for in-field failures after thoracic radiation is poorly defined. We evaluated SBRT as an initial or second course of treatment re-irradiating in a prior high dose region. Thirty-three patients were treated with re-irradiation defined by the prior 30Gy isodose line. Kaplan-Meier estimates were performed for local (LC), regional (RC), distant control (DC), and overall survival (OS). The plans when available were summed to evaluate doses to critical structures. Patient and treatment variables were analyzed on UVA for the impact on control and survival measures. Median follow-up was 17months. Treatment for sequential courses was as follows: (course1:course2) EBRT:SBRT (24 patients), SBRT:SBRT (7 patients), and SBRT:EBRT (3 patients). Median re-irradiation dose and fractionation was 50Gy and 10 fractions (fx), with a median of 18months (6-61) between treatments. Median OS was 21months and 2year LC 67%, yet LC for >1 fraction was 88% (p=0.006 for single vs. multiple). 10 patients suffered chronic grade 2-3 toxicity (6 chest wall pain, 3 dyspnea, 1 esophagitis) and 1 grade 5 toxicity with aorta-esophageal fistula after 54Gy in 3 fx for a central tumor with an estimated EQD2 to the aorta of 200Gy. Tumor control can be established with re-irradiation using SBRT techniques for in-field thoracic failures at the cost of manageable toxicity.
    Radiotherapy and Oncology 01/2014; 110(3). DOI:10.1016/j.radonc.2013.11.017 · 4.36 Impact Factor
Show more